The treatment of peripheral T-cell lymphomas is challenging, as they often display a severe prognosis and lack effective treatment strategies. We will try to answer three burning questions: can we differentiate the initial treatment based on the histotype and the clinical presentation of peripheral T-cell lymphoma patients? Do we require an autologous stem cell transplantation in all patients? Is there room for improvement in the setting of relapsed and refractory disease?
Keywords: azacitidine; brentuximab vedotin; duvelisib; golidocitinib; linperlisib; peripheral T-cell lymphomas; valemetostat.
© 2023 John Wiley & Sons Ltd.